ArticleNature2022
Androgen receptor activity in T cells limits checkpoint blockade efficacy.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 270 papers.
0numbers the graph read from it
0cells of the map it votes in
270citing papers in PubMed
36.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
270 citing papers in PubMed, 371 citations in OpenAlex.
- Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.Nature communications · 2024Trial
- Sex-Biased Immunity: The Hidden Variable in Immuno-oncology.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- Lymph node contraction links sex-biased naive CD8Nature aging · 2026Article
- Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of '-mabs'?The Journal of pathology · 2026Review
- Decoding the metabolic‑immune crosstalk: The role of glutamine and ammonium reprogramming in prostate cancer immune evasion (Review).Oncology reports · 2026Review
- Single-cell and spatial RNA sequencing in prostate cancer.Nature reviews. Urology · 2026Review
- Temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggest a window of opportunity for checkpoint inhibitor therapy in prostate cancer.Journal for immunotherapy of cancer · 2026Article
- Cofilin1-driven cytoskeletal remodeling modulates pan-cancer CD8Cell reports. Medicine · 2026Article
- Sex Steroid Hormone Regulation of T-Cell Function and Antitumor Immunity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- Efficacy of immune checkpoint inhibitors in female patients with cancer: a systematic review and meta-analysis.Science China. Life sciences · 2026Article
- Sex-based survival differences in patients with untreated advanced oesophageal squamous cell carcinoma receiving chemotherapy and immune checkpoint inhibitors: a meta-analysis.ESMO gastrointestinal oncology · 2026Review
- Article
- [A multi-level study of androgen deprivation therapy on the immune microenvironment in prostate cancer].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Article
- Molecular Mechanisms and Immune Regulation in Prostate Cancer: A Review.International journal of molecular sciences · 2026Review
- Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Single-cell profiling of peripheral blood mononuclear cells in diverse men with prostate cancer reveals a fatal disease-associated immune signature.Cancer immunology research · 2026Article
- Article
- HLA Class I Expression Is Associated with Increased Immune Cell Density and PTEN Loss in Prostate Cancer.Molecular cancer research : MCR · 2026Article
- Sex differences in non-reproductive cancers: mechanistic roles of sex-hormone signaling.Cell communication and signaling : CCS · 2026Review
- Reduced Tumor Control in Males Can Result from Impaired CD4+ T-cell Help through the CD40L-CD40 Pathway.Cancer immunology research · 2026Article
210 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
15 authors at 3 institutions in 1 country.
Xiangnan Guan *Department of Biomedical Engineering, Oregon Health and Science University, Portland, OR, USA.
Fanny Polesso *Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA.
Chaojie Wang *Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA.
Archana SehrawatCell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA.
Reed M HawkinsCell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA.ORCID http://orcid.org/0000-0001-8611-2588
Susan E MurrayMolecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR, USA.
George V ThomasKnight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.ORCID http://orcid.org/0000-0001-7416-8840
Breanna CarusoCell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA.ORCID http://orcid.org/0000-0002-1519-8131
Reid F ThompsonDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, OR, USA.
Mary A WoodVA Portland Health Care System, Portland, OR, USA.
Christina HipfingerCell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA.
Scott A HammondClinical IO Discovery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.
Julie N GraffKnight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Zheng XiaDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, OR, USA.ORCID http://orcid.org/0000-0003-3364-8324
Amy E MoranCell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA. moranam@ohsu.edu.ORCID http://orcid.org/0000-0003-1952-7737
Oregon Health & Science University · USAstraZeneca (United States) · USVA Portland Health Care System · US
Funding
TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1MUnderstanding how T cell intrinsic androgen receptor activity influences cell differentiation and dysfunctionR37CA263592 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Amy E Moran · 2021 to 2026
$3.2MProgram in Biomedical SciencesT32GM142619 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Jeffrey Wallace Tyner · 2021 to 2026
$3.2MIn Silico Screening of Alternative Polyadenylation Regulators in CancersK01LM012877 · NLM · OREGON HEALTH & SCIENCE UNIVERSITY · PI XIA, ZHENG · 2018 to 2020
$428kHaemAPA: Characterizing alternative polyadenylation in human blood cellsR21HL145426 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI XIA, ZHENG · 2019 to 2020
$231kNCI NIH HHS P50 CA097186NCI NIH HHS R37 CA263592NHLBI NIH HHS R21 HL145426NIGMS NIH HHS T32 GM142619NIH HHS 1R21 HL145426NIH HHS 5K01 LM012877NIH HHS 5P50 CA097186NLM NIH HHS K01 LM012877Wellcome Trust NS-201812034
Abstract
Immune checkpoint blockade has revolutionized the field of oncology, inducing durable anti-tumour immunity in solid tumours. In patients with advanced prostate cancer, immunotherapy treatments have largely failed
Indexed as
CD8-Positive T-LymphocytesImmunotherapyProstatic NeoplasmsReceptors, AndrogenAndrogen AntagonistsHumansImmune Checkpoint InhibitorsInterferon-gammaMaleTreatment FailureAndrogen AntagonistsImmune Checkpoint InhibitorsInterferon-gammaReceptors, Androgen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.